Previous 10 | Next 10 |
-- Application Based on Results from Pivotal Phase 2b/3 SELECTION Trial -- Foster City, Calif., & Mechelen, Belgium, November 2, 2020, 22.01 CET – Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the applicatio...
GILD reports earnings after-hours. Remdesivir could revive growth in the short term. However, revenue from HIV and HCV could be dead for now. GLPG's R&D pipeline has suffered some setbacks and may not be the boon GILD once thought. The IMMU deal could limit GILD's ability ...
Comprehensive preclinical package elucidates dual mode of action (MoA) and potential broad applicability of salt-inducible kinase (SIK) inhibitors in inflammation Innovative chemistry generated multiple series of SIK compounds with distinct selectivity profiles, aimed at a range ...
Galapagos is now tied tightly to Gilead. The stock price is near at the 52-week low. Filgotinib market penetration will be crucial near term; longer term, the pipeline looks good. For further details see: Galapagos Is A Buy Despite Setback In The U.S.
Galecto has filed proposed terms for an $85 million U.S. IPO. The firm is development treatments for various fibrosis diseases. GLTO has produced impressive trial results to-date. For life science investors with a long-term hold time frame, the IPO is worth considering. ...
Goldman Sachs analyst, Graig Suvannavejh downgraded Galapagos ([[GLPG]] -6.6%) to Sell from Neutral with a PT of €87, down from €108.Suvannavejh adds that he is changing his sales estimates for filgotinib due to a 'meaningful delay in the timing of the U.S. launch given rec...
Galapagos announces topline data from knee osteoarthritis trial. Evelo provides updates for EDP1815 in Atopic Dermatitis and Psoriasis trials. CTI BioPharma initiates NDA process for Pacritinib. For further details see: Galapagos Knee Osteoarthritis Data, And Other News:...
London +1.34%.France +1.53%.Germany +0.57%.European stocks trail the late recovery in U.S. stocks, after closing sharply lower yesterday.Thyssenkrupp (TYEKF) shares bounced more than 17% in early trade after reports that Britain’s Liberty Steel is lining up a takeover bi...
Galapagos (GLPG) -6.1% after-hours, reporting its phase 2 study with partner Servier for their treatment for patients with knee osteoarthritis failed to meet its primary objective.The companies say the primary objective of the Rocella trial was to demonstrate the efficacy of GLPG1972/ S201086...
Mechelen, Belgium and Paris, France, 15 OCTOBER 2020, 22.01 CET; regulated information –Servier and Galapagos NV (Euronext & NASDAQ: GLPG) report that no signal of activity was observed in the topline results in their ROCCELLA Phase 2 trial with GLPG1972/S201086. ROCCELLA...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...